The group's principal activity is to build a portfolio of products with commercial potential in targeted therapeutic areas. The initial area of focus is migraine, where the group has built a portfolio of three product candidates through a combination of innovation and in licensing. Mt 100 is being developed by the group as an oral first-line therapy for the treatment of migraine. The group is developing mt 300 to provide safe, convenient and pain relief for patients needing an injectable therapy for severe migraine attacks. Other migraine therapeutic product candidates include mt 400, being developed as a co-active migraine therapy.
